Maze Therapeutics, Inc. - Common Stock, par value $0.001 (MAZE)

Historical Holders from Q1 2025 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001
Symbol
MAZE on Nasdaq
Shares outstanding
43,496,286
Price per share
$41.45
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
42,970,633
Total reported value
$1,114,223,528
% of total 13F portfolios
0.01%
Share change
+4,153,172
Value change
+$108,250,260
Number of holders
93
Price from insider filings
$41.45
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Maze Therapeutics, Inc. - Common Stock, par value $0.001 (MAZE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Third Rock Ventures IV, L.P. 14% $53,390,091 6,073,958 Third Rock Ventures IV, L.P. 31 Jan 2025
ARCH Venture Fund X, L.P. 9.4% $36,215,266 4,120,053 ARCH Venture Fund X, L.P. 31 Mar 2025
Deep Track Capital, LP 9% +30% $59,431,096 +$13,927,661 3,948,910 +31% Deep Track Capital, LP 30 Jun 2025
Frazier Life Sciences Public Fund, L.P. 7.7% -25% $50,461,371 -$16,531,281 3,352,915 -25% Frazier Life Sciences Public Fund, L.P. 30 Jun 2025
JANUS HENDERSON GROUP PLC 7.3% +22% $83,143,819 +$15,075,261 3,206,472 +22% JANUS HENDERSON GROUP PLC 30 Sep 2025
GV 2019, L.P. 5.5% $21,205,620 2,412,471 Alphabet Holdings LLC 31 Mar 2025
Matrix Capital Management Company, LP 3.5% -37% $42,880,026 -$21,586,725 1,653,684 -33% Matrix Capital Management Company, LP 30 Sep 2025
Foresite Capital Fund IV, L.P. 1.4% -70% $15,790,022 -$47,922,789 608,948 -75% James Tananbaum 30 Sep 2025
As of 30 Sep 2025, Maze Therapeutics, Inc. - Common Stock, par value $0.001 (MAZE) has 93 institutional shareholders filing 13F forms. They hold 42,970,633 shares. of 43,496,286 outstanding shares (99%) .

Top 25 institutional shareholders own 90% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
TRV GP IV, LLC 14% 6,073,958 0% 57% $157,497,731
Frazier Life Sciences Management, L.P. 11% 4,567,274 -0% 3.5% $118,429,415
ARCH Venture Management, LLC 9.5% 4,120,053 0% 22% $106,832,974
Deep Track Capital, LP 9.1% 3,948,910 0% 2.9% $102,395,236
Alphabet Inc. 5.5% 2,412,471 0% 2.6% $62,555,373
a16z Capital Management, L.L.C. 3.9% 1,702,225 0% 3.2% $44,138,694
Matrix Capital Management Company, LP 3.8% 1,653,684 -33% 40% $42,880,026
VANGUARD GROUP INC 3.1% 1,334,955 +218% 0% $34,615,383
BlackRock, Inc. 3% 1,316,016 +114% 0% $34,124,295
VR ADVISER, LLC 2.8% 1,230,769 1.8% $31,913,840
Logos Global Management LP 2.8% 1,227,300 +101% 3.1% $31,823,889
General Catalyst Group Management, LLC 2.4% 1,035,910 0% 0.88% $26,861,146
Woodline Partners LP 2.4% 1,035,229 +10% 0.13% $26,843,488
TRV GP V, LLC 2.2% 950,800 0% 7% $24,654,244
MARSHALL WACE, LLP 1.8% 777,701 +3868% 0.02% $20,165,786
Casdin Capital, LLC 1.7% 758,857 0% 1.6% $19,677,162
JANUS HENDERSON GROUP PLC 1.7% 751,874 -46% 0.01% $19,488,574
Ikarian Capital, LLC 1.7% 740,825 +182% 4.4% $19,209,592
FMR LLC 1.5% 655,614 +18% 0% $17,000,071
ArrowMark Colorado Holdings LLC 1.3% 545,132 0.26% $14,135,273
Foresite Capital Management IV, LLC 1.2% 522,657 -75% 7.4% $13,552,496
BESSEMER GROUP INC 1.1% 481,790 0% 0.02% $12,493,000
GEODE CAPITAL MANAGEMENT, LLC 1.1% 473,549 +105% 0% $12,281,796
HHLR ADVISORS, LTD. 1.1% 457,535 0% 0.29% $11,863,883
Balyasny Asset Management L.P. 1% 433,725 0.02% $11,246,489

Institutional Holders of Maze Therapeutics, Inc. - Common Stock, par value $0.001 (MAZE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 8,670 $359,334 +$144,688 $41.45 3
2025 Q3 42,970,633 $1,114,223,528 +$108,250,260 $25.93 93
2025 Q2 38,836,437 $476,719,891 -$14,337,293 $12.27 74
2025 Q1 40,038,674 $441,393,439 +$441,263,796 $11.01 68